Skip to main content
MedPathMedPath Home
Clinical Trials/NCT01232348
NCT01232348
Completed
Not Applicable

Symbicort Turbuhaler 30/60 Clinical Experience Investigation

AstraZeneca1 site in 1 country3,643 target enrollmentJanuary 2010
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsBronchial Asthma

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Bronchial Asthma
Sponsor
AstraZeneca
Enrollment
3643
Locations
1
Primary Endpoint
Incidence of Adverse Events
Status
Completed
Last Updated
14 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

The purpose of this study is to confirm the safety (ADR related to beta stimulant drugs, unexpected ADRs) and efficacy of Symbicort in daily practice and the control status on bronchial asthma and Patient satisfaction

Registry
clinicaltrials.gov
Start Date
January 2010
End Date
October 2011
Last Updated
14 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • •Patients treated with Symbicort for the first time due to bronchial asthma

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Incidence of Adverse Events

Time Frame: Range of 12 weeks

Secondary Outcomes

  • The level of asthma control(Range of 12 weeks)
  • The level of patient satisfaction with Symbicort(Range of 12 weeks)

Study Sites (1)

Loading locations...

Similar Trials

Completed
Not Applicable
Clinical Experience Investigation of Symbicort Turbuhaler as Maintenance Therapy and Reliever TherapyBronchial Asthma
NCT01711840AstraZeneca2,409
Completed
Not Applicable
Symbicort Turbuhaler 30/60 Specific Clinical Experience InvestigationBronchial Asthma
NCT01232335AstraZeneca1,500
Completed
Not Applicable
Symbicort Turbuhaler 30/60 Special Clinical Experience Investigation for Long-term Use for Chronic Obstructive Pulmonary Disease (COPD) PatientsChronic Obstructive Pulmonary Disease
NCT01713075AstraZeneca1,183
Completed
Phase 3
A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With AsthmaAsthma
NCT02224157AstraZeneca4,215
Completed
Phase 3
Comparison of the Efficacy/Safety of Symbicort® Turbuhaler®,Seretide™ Diskus™ 50/500 µg & Terbutaline Turbuhaler® 0.4 mgAsthma
NCT00242775AstraZeneca2,100